CG100649: Phase IIb started

CrystalGenomics began a double-blind, active-controlled, South Korean Phase IIb trial to evaluate 2 or 4 mg daily CG100649 vs. 200 mg Celebrex celecoxib for 28 days in about 132 OA patients. Pfizer ...